IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma

Genes and Immunity

Volumn 2, Issue 1, 2001, Pages 25-31

  Howell, W M ^a,b   Turner, S J ^a   Bateman, A C ^b   Theaker, J M ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; IL 10; Malignant melanoma

Indexed keywords

INTERLEUKIN 10; PRIMER DNA;

ARTICLE; GENETICS; GENOTYPE; HUMAN; MELANOMA; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TUMOR;

BASE SEQUENCE; DNA PRIMERS; GENOTYPE; HUMANS; INTERLEUKIN-10; MELANOMA; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); SKIN NEOPLASMS;

EID: 0035260890     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6363726     Document Type: Article

References (24)

1. Cress RD, Holly EA. Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians and blacks: an analysis of California cancer registry data, 1988-93. Cancer Causes Control 1997; 8: 245-252.
2. Valverde P, Healy E, Sikkink S et al. The Asp84glu variant of the melanocortin-1 receptor is associated with melanoma. Hum Mol Genet 1996; 5: 1663-1666.
3. Hutchinson PE, Osborne JE, Lear JT et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 2000; 6: 498-504.
4. Strange RC, Ellison T, Ichii-Jones F et al. Cytochrome P450 CYP2D6 genotypes: association with hair colour, Breslow thickness and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma. Pharmacogenetics 1999; 9; 269-276.
5. Wolfel T, Hauer M, Klehmann E et al. Analysis of antigens recognised on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). Int J Cancer 1993; 55: 237-244.
6. Bateman AC, Turner SJ, Theaker JM, Howell WM. HLA-DQB1* 0303 and *0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian population. Tissue Antigens 1998; 52: 67-73.
7. Lee JE, Lu M, Mansfield JF, Platsoucas CD, Reveille JD, Ross MI. Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer stage I or II. Cancer 1996; 78: 758-763.
8. Lulli P, Grammatico P, Brioli G et al. HLA-DR and -DQ alleles in Italian patients with melanoma. Tissue Antigens 1998; 51: 276-280.
9. Fortis C, Foppoli M, Gianotti L et al. Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett 1996; 104: 1-5.
10. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995; 5: 67-68.
11. Yue FY, Dummer R, Geertsen R et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997; 71: 630-637.
12. Huang S, Ullrich SE, Bar-Eli M. Regulation of tumour growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res 1999; 19: 697-703.
13. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene. Eur J Immunogenet 1997; 24: 1-8.
14. Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphisms in interferon-γ, interleukin-10, transforming growth factor-β1 and tumour necrosis factor-α genes: a technical report. Transplant Immunol 1998; 6: 193-97.
15. Clark WH Jr, Elder DE, Guerry D IV et al. Model predicting survival in stage I melanoma based on tumour progression. J Natl Cancer Inst 1989; 81: 1893-1904.
16. Mackie RM, Smyth JF, Soutar DS et al. Malignant melanoma in Scotland 1979-1983. Lancet 1985; 2: 859.
17. Mackie R, Hunter JA, Aitchison TC et al. Cutaneous malignant melanoma, Scotland, 1979-1983. The Scottish Melanoma Group. Lancet 1992; 339: 971-975.
18. Fiorentino DF, Zlotnik A, Vieira P et al. IL-10 acts on the antigen presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444-3451.
19. Chen Q, Daniel V, Maher D, Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994; 56: 755-760.
20. Dummer W, Bastian BC, Ernst N, Schanzle C, Schwaaf A, Brocker EB. Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer 1996; 66: 607-610.
21. Zheng LM, Ojcius DM, Garaud F et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996; 184: 579-584.
22. Kundu N, Beaty TL, Jackson MJ, Fulton AM. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst 1996; 88: 536-541.
23. Beahrs OH, Myers MH. Manual for staging of cancer. American Joint Committee on Cancer. 2nd Edition. JB Lippincott: Philadelphia, 1983: 117-122.
24. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification and sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-235.